Esketamine for treatment-resistant depression in adults
| Autor: | Chiara Gastaldon, Pier Francesco Laurenzi, Georgios Schoretsanitis, Davide Papola, Ioana Alina Cristea, Florian Naudet, Giovanni Ostuzzi, Corrado Barbui |
|---|---|
| Přispěvatelé: | Università degli studi di Verona = University of Verona (UNIVR), Universität Zürich [Zürich] = University of Zurich (UZH), The Zucker Hillside Hospital, Università degli Studi di Pavia = University of Pavia (UNIPV), Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou [Rennes], University of York, National Institute for Health Research, NIHR, University of Bristol |
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews, 2022, 2022 (1), pp.CD015071. ⟨10.1002/14651858.CD015071⟩ Cochrane Database Syst Rev |
| ISSN: | 1465-1858 |
| DOI: | 10.1002/14651858.CD015071⟩ |
| Popis: | International audience; Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. The main aim of this Cochrane review is to assess the efficacy and tolerability of esketamine for treatment-resistant depression. Secondary aims are to assess the risk of specific adverse events during esketamine treatment, and its acceptability. Copyright © 2022 The Cochrane Collaboration. Published by John Wiley and Sons, Ltd. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|